Coya Therapeutics, Inc. announced successful meetings with the FDA following a pre-IND meeting and a Type C meeting intended to seek advice from the Agency to reach alignment on multiple aspects of the planned development program in support of an IND application of COYA 302 for the treatment of Amyotrophic Lateral Sclerosis or ALS. The company said it has obtained constructive feedback and has reached alignment on key areas involved in the development of COYA 302, including CMC, preclinical and clinical activities for the IND application.
Fred Grossman, President and Chief Medical Officer of Coya, said: "This important feedback allows us to advance our development program in ALS with a planned double-blind controlled study, with the potential for bringing forward a much-needed therapy for ALS patients."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.